Pfizer announced positive topline results from the MagnetisMM-5 Phase 3 trial, showing that ELREXFIO (elranatamab) as monotherapy significantly improves progression-free survival versus standard-of-care DPd in adults with relapsed or refractory multiple myeloma who have had at least one prior therapy.

The trial met its primary endpoint and surpassed the interim efficacy target; overall survival remains a secondary endpoint and was not mature at the interim analysis.

In a 497-patient, 26-country study, ELREXFIO monotherapy was compared against daratumumab plus pomalidomide and dexamethasone, with benefits confirmed by blinded independent central review.

Analysts’ responses vary, with some firms maintaining strong ratings and others adjusting price targets amid ongoing patent and competitive dynamics surrounding the therapy.

Safety and tolerability were in line with ELREXFIO’s known profile, with no new safety signals identified, and detailed results to be presented at a future medical congress.

The report includes context on multiple myeloma prevalence and relapse dynamics, and discusses the potential impact of earlier intervention along with REMS requirements for safety monitoring such as CRS and neurologic events.

MagnetisMM-5 enrolled adults with relapsed/refractory disease and excluded certain conditions (smoldering myeloma, plasma cell leukemia, amyloidosis, POEMS, recent stem cell transplant, prior BCMA-targeted agents, recent live vaccines, or concurrent investigational products).

ELREXFIO is a subcutaneously delivered BCMA-CD3 bispecific antibody that redirects T cells to target myeloma cells and is approved in multiple countries for heavily pretreated RRMM, with ongoing development in monotherapy and combinations under the MagnetisMM program.

Participants had prior lenalidomide and proteasome inhibitor exposure and received a two-step-up priming dosing regimen before weekly 76 mg injections, with dose adjustments based on response.

Overall survival remains a key secondary endpoint and results will be discussed with health authorities and presented at a future medical congress as MagnetisMM-5 continues.

Pfizer emphasizes ELREXFIO’s potential across multiple lines of therapy, including monotherapy and combinations, with an eye toward earlier treatment settings.

ELREXFIO’s safety profile aligns with prior data, including risks of cytokine release syndrome and neurologic events, and its global regulatory footprint includes accelerated approval in the U.S. and EU labeling in various settings.